LUND UNIVERSITY

Prostaglandin D(2) induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig.

Larsson Callerfelt, Anna-Karin; Hagfjård, Annika; Dahmén, Sven-Erik; Adner, Mikael

Published in:
European Journal of Pharmacology

DOI:
[10.1016/j.ejphar.2011.07.046](https://doi.org/10.1016/j.ejphar.2011.07.046)

2011

[Link to publication](#)

Citation for published version (APA):
Larsson Callerfelt, A-K., Hagfjård, A., Dahmén, S-E., & Adner, M. (2011). Prostaglandin D(2) induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig. *European Journal of Pharmacology*, 669(1-3), 136-142. <https://doi.org/10.1016/j.ejphar.2011.07.046>

Total number of authors:
4

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Prostaglandin D₂ induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig

Anna-Karin Larsson ^{a, b*}, Annika Hagfjärd ^a, Sven-Erik Dahlén ^a and Mikael Adner ^a

^a Experimental Asthma and Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, ^b Lung Biology, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden

E-mail addresses:

Anna-Karin.Larsson@med.lu.se

Annika.Hagfjard@gmail.com

Sven-Erik.Dahlen@ki.se

Mikael.Adner@ki.se

** Corresponding author:*

Anna-Karin Larsson, Lung Biology, Department of Experimental Medical Science, BMC D12, Lund University, 221 84 Lund, Sweden. Tel: +46 462229441

E-mail: Anna-Karin_L.Larsson@med.lu.se

Abstract

Prostaglandin D₂ (PGD₂), released through mast cell activation, is used as a non-invasive biomarker in patients with asthma. Since PGD₂ can elicit opposing effects on airway tone via activation of the PGD₂ receptors DP₁ and DP₂ as well as the thromboxane receptor TP, the aim of this study was to characterize the receptors that are activated by PGD₂ in the guinea pig lung parenchyma. PGD₂ and the thromboxane analogue U46619 induced concentration-dependent contractions. U46619 was more potent and caused stronger effect than PGD₂. The specific TP receptor antagonist SQ-29548 and the combined TP and DP₂ receptor antagonist BAYu3405 concentration-dependently shifted the curves for both agonists to the right. The DP₁ receptor agonist BW245 induced a weak relaxation at high concentrations, whereas the DP₁ receptor antagonist BWA868C did not affect the PGD₂ induced contractions. The specific DP₂ receptor agonist 13,14-dihydro-15-keto -PGD₂ showed neither contractile nor relaxant effect in the parenchyma. Furthermore, studies in precision-cut lung slices specified that airways as well as pulmonary arteries and veins contracted to both PGD₂ and U46619. When the lung parenchyma from ovalbumin sensitized guinea pigs were exposed to ovalbumin, both thromboxane B₂ and PGD₂ were released. Ovalbumin also induced maximal contractions at similar level as PGD₂ in the parenchyma, which was partly reduced by SQ-29548. These data show that PGD₂ should be recognized as a TP receptor agonist in the peripheral lung inducing contraction on airways, arteries and veins. Therefore, a TP receptor antagonist can be useful in combination treatment of allergic responses in asthma.

Keywords: Guinea pig; lung parenchyma; ovalbumin; precision cut lung slices; prostaglandin D₂; thromboxane

1. Introduction

Prostaglandin D₂ (PGD₂), secreted during mast cell activation (Dahlen and Kumlin, 2004), and its metabolite 9 α -11 β PGF_{2 α} are used as non-invasive biomarkers in patients with asthma (O'Sullivan et al., 1996). PGD₂ is part of the acute asthmatic airway response; levels of this mediator can be found within minutes in BAL fluid and at 150-fold higher biologically active levels than before the exacerbation (Liu et al., 1991). In addition to the acute reaction, PGD₂ has through recruitment of inflammatory cells been suggested to contribute to the formation of the chronic asthmatic inflammation and subsequent airway remodelling (Balzar et al., 2011).

PGD₂, generated from arachidonic acid, is converted to PG via cyclooxygenase (COX) (Vane, 1971) and PGD synthase (Urade and Eguchi, 2002). There are two distinct types of PGDS; hematopoietic (H-PGDS) and lipocalin-type (L-PGDS). H-PGDS is highly expressed in mast cells, eosinophils, macrophages, and lymphocytes as well as structural cells such as epithelial cells and fibroblasts, whereas L-PGDS is mainly expressed in the central nervous system and heart (Okano et al., 2006). PGD₂ exits the cell via a carrier-mediated process and activates specific G-protein coupled receptors on target cells. PGD₂ is classified to mediate its effect via the DP₁ (Coleman et al., 1994) and the DP₂ (CRTH₂) receptors (Abe et al., 1999), but also known to act via the receptor for thromboxane A₂ (TXA₂), the TP receptor (Hamid-Bloomfield et al., 1990). The DP₁ receptor is widely distributed in airway and vascular smooth muscle, blood platelets, airway epithelium and nervous tissue (Coleman et al., 1994; Matsuoka et al., 2000; Norel et al., 1999). PGD₂ has also an important chemotactic role via activation of the DP₂ receptor (Abe et al., 1999), which is mainly expressed on Th2 cells and eosinophils (Abe et al., 1999) but also on human airway smooth muscle (Abe et al., 1999; Parameswaran et al., 2007). The TP receptors are expressed on bronchial and vascular smooth muscle cells, blood

platelets and myofibroblasts (Capra et al., 2003; Coleman et al., 1994) and are known to mediate a strong and long-lasting contraction in these tissues (Held et al., 1999; Ressmeyer et al., 2006). PGD₂ may thus have broad actions since activation of multiple receptors can elicit theoretically opposing effects on airway tone.

Although the lung parenchyma is a complex tissue, the action in the peripheral lung is of importance to study since asthma is suggested to be a disease of the small airways (van den Berge et al., 2011). Especially the action of PGD₂ is of interest since it has been shown that mast cells are located peripherally around small bronchi, vessels and further out to the alveoli (Andersson et al., 2009) and thus may not only affect airways. The aim of this study was therefore to characterize the receptors that are activated by PGD₂ in the peripheral lung and subsequently investigate the significance of this effect in allergen-induced contractions. The guinea pig parenchyma is particularly suitable as it has been shown to respond to many agonists similar to human (Canning and Chou, 2008; Ressmeyer et al., 2006).

2. Methods

2.1. Animals and ovalbumin-sensitization

Male Dunkin Hartley guinea pigs (300–350 g b.w.) were used. In one part of the experiments the guinea pigs were sensitized to ovalbumin at least four weeks prior to experiments as previously described (Larsson et al., 2005). The study was approved by the regional committee of animal experimentation ethics (N127/04, N63/07).

2.2. Lung parenchymal strips and organ bath experiments

The animals were sacrificed by an overdose of inhaled CO₂ and the heart-lung-package was quickly removed and placed in ice-cold Tyrode's solution (prepared each day, containing NaCl 149.2 mM, KCl 2.7 mM, NaHCO₃ 11.9 mM, glucose 5.5 mM, CaCl₂ 1.8 mM, MgCl₂ 0.5 mM, NaH₂PO₄ 0.4 mM). The lung parenchyma was cut parallel to the peripheral margins, yielding four to eight strips, each having a size of 2×2×20 mm and a weight of approximately 60 mg. The parenchymal strips were set up at a resting tension of 4.0 mN in 5 ml organ baths filled with Tyrode's solution, bubbled with carbogen gas (6.5% CO₂ in O₂) to keep a pH of 7.4 at 37°C. Changes in smooth muscle tension, contractions and relaxations, were recorded via isometric force-displacement transducers connected to a Grass polygraph. After an equilibration period of 90 min and washes each 15 min, histamine was added as a control of the parenchymal strip reactivity. Preparations displaying contraction responses less than 1.0 mN to 30 µM of histamine were excluded from further experiments. Another wash and equilibration period between histamine and treatment period was performed. All antagonists were given 15 min before the challenges. For study the effect of different agonists, the parenchymal strip was exposed to cumulative concentrations. To study the relaxation the parenchyma was pre-contracted with 10 nM of LTD₄ generating a 50% contraction. To study the allergic early phase reaction, ovalbumin was added as cumulative

challenge of increasing concentrations every 10 min without changing bath fluid. Maximum contractions of the preparation were determined with histamine (1 mM), acetylcholine (1 mM) and potassium chloride (KCl; 50 mM) at the end of each experiment, and other responses were expressed as percent of maximum contractions.

2.3. Measurements of released mediators with enzyme immunoassays

A 1 mL aliquot of organ bath fluid was collected from each organ bath and immediately frozen at -20°C. The samples were taken at the end of the equilibration period to obtain basal mediator release from the tissue and at the obtained contractile plateau after challenge with ovalbumin 1000 ng/ml. Enzyme immunoassay (EIA) analyses of the prostanoids TXA₂ and PGD₂ were performed according to the manufacturer's instructions. TXA₂ was measured as the stable metabolite TXB₂. PGD₂ was measured as PGD₂-mox. The assay detection limits in the bath fluid levels were 7.8 pg/ml. The EIA specificity for the different mediators to interfere with each other was less than 0.01%, with the exception of the EIA kit for TXB₂ that cross reacted with PGD₂ (0.53%).

2.4. Precision-cut lung slices

Guinea pig precision-cut lung slices were prepared as previously described (Ressmeyer et al., 2006). Briefly, the lung was filled through the trachea with a low melting-point agarose solution (0.75%) containing salbutamol (1 mM). Lung tissue cores were prepared and cut into 220-mm-thick slices with a Krumdieck tissue slicer (Alabama Research and Development, Munford, AL, USA). Tissue slices were incubated at 37°C in a humid atmosphere in minimal essential medium supplemented with sodium pyruvate, amino acids, vitamins and glutamine. The medium was changed on a regular basis during four hours in order to remove the agarose and cell debris from the tissue. Salbutamol was added to the medium during the first three

hours. The slices were then imaged using an analogue (JAI 2040; JAI Pulnix, Alzenau, Germany) or digital camera (IRB640; Visitron Systems, Munich, Germany). For measurements, slices with comparable airway and vessel size were selected. Bronchoconstriction or vasoconstriction was expressed as airway/vessel area as the percentage of the initial area. A control image was taken before cumulative addition of U46619 or PGD₂ and frames were recorded every 30 sec for 20 min.

2.5. Data analysis and statistical procedures

All data are presented as mean $\pm$ standard error of the mean (S.E.M.). Statistical analyses were made for paired and unpaired observations by Student's t-test or analyses of variances (ANOVA) followed by the post hoc tests Bonferroni's t-test. A P-value of less than 0.05 was considered significant. To provide estimates of maximal effect ($E_{\max}$), midpoint location (pEC_{50}) and Hill slope (n_H), agonist concentration-effect curve data from individual tissues were fitted to the Hill equation using an iterative, least square method (GraphPad Prism, San Diego, USA). For the Schild plot analysis, the concentration-response curves with antagonists were set at a global shared maximum assuming competitive antagonism. If the value of the slope was found not to be significantly different from unity a second fit was performed for the calculation of pK_B values with the slope constrained to unity.

2.6. Drugs and chemical reagents

NaCl, KCl, CaCl₂, MgSO₄, NaHCO₃, KH₂PO₄ and glucose were obtained from VWR International (West Chester, Pennsylvania, USA). Histamine dihydrochloride, acetylcholine, ovalbumin (chicken egg albumin, grade II), agarose, salbutamol, dimethylsulfoxid (DMSO) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). 3R-[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (BAYu3405,

139 Ramatroban) was purchased from Bayer AG (Wuppertal, Germany). PGD₂, (4S)-(3-[(3R,S)-
140 3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid (BW245C), LTD₄,
141 9,11-dideoxy-9 α ,11 α -methanoepoxy PGF_{2 α} (U46619), PGF_{2 α} , [1S-[1 α ,2 α (Z),3 α ,4 α]]-7-[3-[[2-
142 [(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid
143 (SQ-29548), 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-4-
144 imidazolidineheptanoic acid (BWA868C), 9 α ,11 β -PGF₂ and 13,14-dihydro-15-keto (DK)-
145 PGD₂ were bought from Cayman Chemical (Ann Arbor, MI, USA). LTD₄ was from Cascade
146 Biochemicals Ltd. (Reading, UK). The EIA kits for TXB₂ and PGD₂-mox were obtained from
147 Cayman Chemicals (Ann Arbor, Michigan, USA). Stock solutions of 1 mM LTD₄ and
148 prostanoids were dissolved in 50% ethanol-water and then diluted in 20% ethanol-water.
149 Ovalbumin was dissolved in 0.9% NaCl. The other drugs were dissolved and diluted in
150 Tyrode's solution or millipure water. Dilutions of drugs were freshly made from the stocks for
151 each experiment. The drugs were present in the organ bath fluid during the remaining
152 experiment. 0.1% DMSO was added as a control and did not influence the baseline or
153 cumulative contractions to ovalbumin.

3. Results

3.1. The TP receptor is the main contractile receptor for PGD₂, TXA₂ and PGF_{2α}

PGD₂ induced concentration-dependent contractions in the lung parenchyma (Fig. 1A and B). The contraction ($79.8 \pm 8.5\%$), obtained at the highest concentration used (100 μM), was according to the non-linear regression analysis not the maximal effect. The inability of PGD₂ to reach the maximum capacity of the tissue contrasted to U46619 (Fig. 1C and D), which induced a contraction reaching similar or higher maximum effect as the high concentrations of histamine, acetylcholine and potassium chloride used as the reference at the end of each experiment ($108 \pm 4.6\%$) and with a 30-fold greater potency than PGD₂ (pEC₅₀: 6.68 ± 0.24 and 5.14 ± 0.22 , respectively). However, the concentration-response curves for both PGD₂ and U46619 were markedly shallow with Hill slopes significantly below 1 (0.58 ± 0.04 and 0.53 ± 0.05).

When preparations were treated with the competitive TP receptor antagonist SQ-29548, the concentration-response curve to PGD₂ was shifted to the right (Fig. 1A). Pretreatment with 0.1 or 1 μM of SQ-29548 gave rise to significantly different pEC₅₀ values (4.7 ± 0.1 and 4.2 ± 0.1 , respectively) compared to control (5.4 ± 0.3 ; table 1). At these concentrations of SQ-29548, the Hill slope was significantly higher than for the control. Further experiments with the combined TP and DP₂ receptor antagonist BAYu3405 (Fig. 1B) also produced concentration-dependent rightward shifts of the PGD₂ induced concentration-response curve. Preparations treated with 0.1 or 1 μM BAYu3405 displayed significantly different pEC₅₀ values (4.3 ± 0.1 and 4.0 ± 0.2 , respectively) compared to controls (5.2 ± 0.2 ; table 1).

In preparations pre-treated with 0.1 or 1 μM SQ-29548, U46619 displayed a concentration-dependent shift of the concentration-response curve and the pEC₅₀ values (6.0 ± 0.2 and $5.3 \pm$

0.2, respectively) were significantly lower than control preparations (6.8 ± 0.2 ; Fig. 1C). When BAYu3405 was used as TP receptor antagonist, the same pattern was shown again with significantly lower pEC_{50} values for 0.1 or 1 μ M BAYu3405 (5.4 ± 0.1 and 5.0 ± 0.1 , respectively), compared to control (7.2 ± 0.4 ; Fig. 1D). To quantify the antagonistic capacity for SQ-29548 and BAYu3405, Schild plot analysis was performed, assuming that the agonist curves reached the similar maximum and ignoring the absence of parallel shifts. Although the antagonists showed a linear regression statistically not deviating from unity it was a tendency for lower Schild slopes for both SQ-29548 (0.89 ± 0.08 for PGD_2 ; $P = 0.250$; and 0.85 ± 0.18 for U46619; $P = 0.521$) and BAYu3405 (0.71 ± 0.25 for PGD_2 ; $P = 0.375$; and 0.84 ± 0.13 for U46619; $P = 0.364$). The pK_B values for the experiments with SQ-2954 rendered a 10-fold differences between PGD_2 and U46619 (7.14 ± 0.08 and 8.17 ± 0.18 , respectively) whereas no significant difference was seen in the experiments with BAYu3405 (7.82 ± 0.15 and 7.60 ± 0.16 for PGD_2 and U46619, respectively).

To test if the difference between PGD_2 and U46619 could relate to metabolism of PGD_2 , into a compound activating other receptors, the early PGD_2 metabolite $9\alpha,11\beta$ -PGF₂ was studied. $9\alpha,11\beta$ -PGF₂ yielded a weaker response than both U46619 and PGD_2 , reaching only about 30 % of the maximum contraction (Fig. 2A). The low efficacy of $9\alpha,11\beta$ -PGF₂ did not make it meaningful to calculate pEC_{50} values. Since there is structural similarity between $9\alpha,11\beta$ -PGF₂ and the FP receptor agonist PGF_{2 α} (Komoto et al., 2004), PGF_{2 α} may also be involved in contractions mediated by PGD_2 and its metabolites. The effect of PGF_{2 α} was almost identical to the effect of its stereoisomer $9\alpha,11\beta$ -PGF₂ (Fig. 2B). Pretreatment with the TP receptor antagonist SQ-29548 significantly abolished the contractions induced by $9\alpha,11\beta$ -PGF₂ ($P < 0.001$) (Fig. 2A) and PGF_{2 α} ($P < 0.001$) (Fig. 2B), indicating that PGF_{2 α} acted as a TP receptor agonist in the guinea pig peripheral lung preparation.

204

205 *3.2. The DP₁ receptor induce a weak relaxation of peripheral lung tissue*

206 The DP₁ receptor has been described to mediate relaxation of vascular and bronchial SMCs
207 (Norel, 2007). Therefore, it was investigated if the DP₁ receptor may mediate relaxation of
208 peripheral lung tissue. Lung strips were treated with cumulative concentrations of the DP₁
209 receptor agonist BW245C after pre-contraction with 10 nM of LTD₄. The pre-contracted
210 strips relaxed at the highest concentration of BW245C (10 µM) (Fig 3A). Based on these
211 results, experiments with the DP₁ receptor antagonist BWA868C (0.1 and 1 µM) were
212 performed with the hypothesis that inhibition of the DP₁ receptor should enhance the PGD₂
213 induced contractions. However, the BWA868C treated preparations yielded pEC₅₀ values for
214 PGD₂ that were not significant different from controls (Fig. 3B and table 2).

215

216 *3.3. The DP₂ receptor induce neither contraction nor relaxation*

217 Since BAYu3405 is both a TP and DP₂ receptor antagonist, the DP₂ receptor mediated
218 response in the parenchyma was investigated. Cumulative concentrations of the DP₂ receptor
219 agonist DK-PGD₂ were added to the lung preparations both before and after pre-contraction
220 with LTD₄. DK-PGD₂ up to 10 µM generated neither significant contraction nor relaxation of
221 the peripheral lung tissue (n=5, data not shown).

222

223 *3.4. The effects of PGD₂ and U46619 in airways and pulmonary vessels in precision-cut lung* 224 *slices*

225 Since the lung parenchyma preparation consists of both airways and vessels, precision cut
226 lung slices were examined to study the contractile effect of PGD₂ and U46619 in peripheral
227 airways and pulmonary arteries and veins. Indeed, PGD₂ induced contractile effects in
228 airways (pEC₅₀: 6.8 ± 0.1) as well as both pulmonary veins (pEC₅₀: 7.2 ± 0.2) and arteries

(pEC₅₀: 6.0 ± 0.2; Fig. 4A). U46619 induced similar strong contractile responses but was significantly more potent in airways (pEC₅₀: 8.9 ± 0.2), veins (pEC₅₀: 9.2 ± 0.2) and arteries (pEC₅₀: 8.1 ± 0.2) in the lung parenchymal preparation (Fig. 4B).

3.5. Role of prostanoids on antigen-induced contractions

Since the contractile effect of both PGD₂ and U46619 was mediated through the TP receptor, experiments with SQ-29548 were performed to study the significance of this receptor in the early allergic reaction. Thus, cumulative challenge with ovalbumin on parenchymal strips from sensitized guinea pigs caused a concentration-dependent contraction that reached about 60-70% of the maximum contraction. Pre-treatment with SQ-29548 partly decreased the ovalbumin-induced contraction (P < 0.01). Analysis of the bath fluid after challenge with ovalbumin (1 µg/mL) showed that TXB₂ (1021 ± 325 fmol/g; n=6) was released in 20-fold higher concentration than PGD₂ (53 ± 6 fmol/g; n=6). Synthesis before ovalbumin stimulation was 61 ± 51 fmol/g for TXB₂ and not detectable for PGD₂.

4. Discussion

It was found that the predominant effect of PGD₂ in the peripheral lung is a contractile effect which is mediated through activation of TP receptors situated on airways as well as arteries and veins in the parenchymal lung tissue. A minor relaxant effect was found to be mediated through the DP₁ receptor and no effect was found to be mediated through the DP₂ in the present study. When inducing ovalbumin activation of sensitized parenchymal strips, both TXA₂ and PGD₂ were released. Ovalbumin also induced contractions that were partly mediated through activation of the TP receptor. Thus, a TP receptor antagonist can be useful to block the contractile action of TXA₂ and PGD₂ in allergic reactions in the airways (Beasley et al., 1989).

PGD₂ and the TP receptor agonist U46619 induced both concentration-response curves with Hill slopes clearly lower than 1, indicating a complexity in the contractile action. One possibility that could explain these shallow curves is if the effects were due to action through more than one receptor. However, since the selective TP (SQ-29548 (Abramovitz et al., 2000); and the dual TP/DP₂ (BAY u3405 (Sugimoto et al., 2005)) receptor antagonists caused right-ward shifts of the concentration-response curve to PGD₂, this indicated, as in line with previous observations (Hamid-Bloomfield et al., 1990; McKenniff et al., 1991), that the TP receptor mediates the main part of the PGD₂-induced contraction. As U46619 induced both stronger contraction and was more potent than PGD₂, the data indicated, in accordance with the much lower affinity for PGD₂ to the TP receptor (Abramovitz et al., 2000), that the responses were mediated through the TP receptor. On the other hand, the curves for the antagonist were not shifted in parallel. Although fully concentration-response curves of PGD₂ were not able to obtain due to the high concentration needed, a clear trend to increased Hill slope with increasing concentration of antagonists was found for both the agonists, mutually

with SQ-29548 and BAY u3405. It is possible that the reason for this increase is due to that both PGD₂ and U46619 have shown the capacity to bind to almost all prostanoid receptors (Abramovitz et al., 2000). Thus, at the higher concentrations of the agonists used for the antagonist experiments, the activation of the TP receptor simultaneously with one or more prostanoid receptors cause an additional or a synergistic effect.

Although the Schild plot slopes did not significantly deviate from unity there was a trend to lower slope values, which may be due to actions of more than one receptor, especially at the higher concentrations of the agonists. Also the discrepancy of the pK_B values for SQ-29548 and not BAY u3405 between the agonists can indicate that another receptor than the TP receptor is activated. The pK_B values for BAY u3405 (7.82 and 7.60 for PGD₂ and U46619, respectively) are in line with presented earlier in guinea pig lung strips (7.7 with U46619 as agonist; (Norman et al., 1992)) whereas the pK_B values for SQ-29548 was 10 fold lower for BAY u3405 (7.14) than for U46619 (8.17) as agonists (range from 7.7 to 8.7 in guinea pig; (Dube et al., 1992; Norman et al., 1992). Since it has been shown that U46619 do not activate the DP₂ receptor (Monneret et al., 2001), the lower pK_B value for SQ-29548 from the PGD₂ experiments can be due to activation of DP₂ receptors. However, as described in this study, a negligible effect is shown when this receptor is selectively activated. Thus, from these experiments the reason for the difference of the pK_B values for SQ-29548 cannot be completely concluded. Taking all these complexities of the actions of the agonists both in absence and presence of antagonism in consideration, the clear antagonism with both these known TP receptor antagonists indicates that the main action of PGD₂ goes through the TP receptor.

The major PGD₂ metabolite, 9 α ,11 β -PGF₂, induced a weak contraction of the peripheral lung that was blocked by SQ-29548 indicating that the breakdown of PGD₂ in this assay do not cause activation of any further receptor than PGD₂ by itself. PGF_{2 α} is a stereoisomer to 9 α ,11 β -PGF₂ and closely structurally related to PGD₂ (Sandig et al., 2006). Thus, one possibility was that PGD₂ also acted through FP receptors (Kiriyaama et al., 1997). Since there are no specific receptor antagonists available for the FP receptor we chose to investigate how the response to PGF_{2 α} could be blocked by SQ-29548. However, as the effect of PGF_{2 α} was abolished by SQ-29548 it is unlikely that PGD₂ mediate any major effect through the FP receptor. Altogether, these data implicate that PGF_{2 α} , which along with PGD₂ has been shown to be released after antigen challenge in guinea pig lung (Dawson et al., 1976), also is part of the TP receptor mediated constriction of the peripheral lung.

The DP₁ receptor has been shown to mediate relaxation of the bronchioles in response to PGD₂ and may thus serve as protection in a situation of bronchoconstriction (Norel et al., 1999). Studies have also shown that rabbit jugular vein preparations treated with the DP₁ receptor agonist BW245C relaxed concentration-dependently (Lydford et al., 1996). Nevertheless, the DP₁ receptor agonist only weakly relaxed the parenchymal lung tissue in the present study. Furthermore, the DP₁ receptor antagonist BWA868C did not affect the PGD₂ induced contractions. Since the DP₂ receptor agonist did not induce contractions or relaxations in this lung preparation, this point towards that the main action for PGD₂ on airway inflammation is the known induction of chemotaxis of eosinophils, basophils and Th2 cells in guinea pigs (Liu et al., 2005) rather than direct responses on the airway smooth muscle.

During the control situation, both agonists induced shallow concentration-response curves in the parenchymal strips. Except for activation on more than one receptor, these shallow curves

can be due to the action of several smooth muscle components, such as small airways and vessels (Evans and Adler, 1981), that not react with similar potencies and maximal effects. In the precision-cut lung slice experiments, the potency difference between PGD₂ and U44619 of the three studied components was similar as in the parenchymal strips (approximately 100-fold) indicating similar contractile actions for the agonists during the control situation. However, a clear difference was obtained between the components, especially the pulmonary arteries compared to the airways and pulmonary veins with a both lower potency and maximal effect in the arteries, suggesting that this is the reason for the shallow control curves for both PGD₂ and U46619. Actually, it is indicated that not only airways and vessels but also pleural cells, alveolar ducts and interstitial cells are activated by TP receptor agonists (Wong et al., 1992). Thus, it is possible that these more peripheral located contractile units, which not easily can be measured in precision-cut lung slices, together with the airways and vessels are activated in a serial manner causing the described shallow concentration-response curves for the two agonists.

Allergen-challenge with ovalbumin showed that both PGD₂ and TXA₂, the latter measured as TXB₂, are released from the distal lung tissue and may be important mediators of the allergen-induced bronchoconstriction in the peripheral lung. Previous studies in this model have shown that also histamine, leukotrienes and PGE₂ are generated after ovalbumin stimulation (Larsson et al., 2009). The 20-fold higher level of TXB₂ in this study is similar to the levels which have been seen in effluent from ovalbumin exposed isolated perfused and ventilated guinea pig lung (Selg et al., 2008). That TXA₂ also is released from mast cells has been shown in studies of the human mast cell line HMC-1 (Macchia et al., 1995). However, human purified sinus mast cells showed a 10-fold higher level of PGD₂ than TXB₂ after IgE stimulation (Mita et al., 1999) suggesting that clear species or anatomical differences exist.

353

354 Previously it has been shown that anti-histamine or 5-LO inhibitor alone has no inhibitory
355 effect on the antigen-induced contraction in guinea pig lung parenchyma (Jonsson and
356 Dahlen, 1994; Larsson et al., 2007). Furthermore, it has been shown that the allergen induced
357 contraction in the peripheral lung of the guinea pig needs to be antagonised or inhibited via
358 several mediator pathways in order to significantly attenuate the contraction (Larsson et al.,
359 2007; Ressmeyer et al., 2006). However, in the present study we found that the TP receptor
360 antagonist significantly inhibited part of the ovalbumin-induced contractions. Thus, the
361 experimental results suggest that TP receptors mediate a significant component of the
362 allergen-induced contractions in this model of the peripheral lung. The explanation, indicated
363 by our findings, may be that several COX-products released by the antigen-challenge (PGD₂,
364 TXA₂ and PGF_{2α}; (Dawson et al., 1976) all act on TP receptors.

365

366 The present study highlights that the parenchymal constriction induced by PGD₂ should be
367 attributed to its properties as a TP receptor agonist. Even though PGD₂ may have minor role
368 as an agonist in the allergen-induced contraction in guinea pigs, since it is both released in
369 lower amount and have lesser effect than TXA₂, the role in human may be of great importance
370 due to the high amount of mast cell release (Mita et al., 1999). Accordingly, the contractile
371 effect of PGD₂ in human airways has also been shown to be antagonized by BAY u3405
372 (Magnussen et al., 1992), which can be important to bear in mind when considering the
373 treatment of early asthmatic responses. Furthermore, the results here are consistent with other
374 studies showing that the allergen response needs to be antagonised or inhibited via several
375 mechanisms to attenuate the contraction (Jonsson and Dahlen, 1994; Roquet et al., 1997; Selg
376 et al., 2009). In this concept, therapy with TP receptor antagonists should be considered as
377 one important component to reduce early asthmatic responses in patients.

Acknowledgement

We would like to express our gratitude to Margareta Andersson for skillful technical assistance and we would like to thank Swedish Research Council in Medicine and Health, Swedish Heart and Lung foundation, Vinnova Chronic inflammation - diagnostic and therapy (CIDaT), the Crafoord Foundation, the Stockholm County Council Research Funds (ALF), Karolinska Institutet , the Tore Nilsson Foundation and the Swedish Society of Medicine for financial support.

References

- Abe, H., Takeshita, T., Nagata, K., Arita, T., Endo, Y., Fujita, T., Takayama, H., Kubo, M., Sugamura, K., 1999. Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemoattractant receptor family. *Gene* 227, 71-77.
- Abramovitz, M., Adam, M., Boie, Y., Carriere, M., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N.M., Belley, M., Gallant, M., Dufresne, C., Gareau, Y., Ruel, R., Juteau, H., Labelle, M., Ouimet, N., Metters, K.M., 2000. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. *Biochim. Biophys. Acta* 1483, 285-293.
- Andersson, C.K., Mori, M., Bjermer, L., Lofdahl, C.G., Erjefalt, J.S., 2009. Novel site-specific mast cell subpopulations in the human lung. *Thorax* 64, 297-305.
- Balzar, S., Fajt, M.L., Comhair, S.A., Erzurum, S.C., Bleecker, E., Busse, W.W., Castro, M., Gaston, B., Israel, E., Schwartz, L.B., Curran-Everett, D., Moore, C.G., Wenzel, S.E., 2009. Mast cell phenotype, location, and activation in severe asthma: data from the severe asthma research program. *Am. J. Respir. Crit. Care Med.* 183, 299-309.
- Beasley, R.C., Featherstone, R.L., Church, M.K., Rafferty, P., Varley, J.G., Harris, A., Robinson, C., Holgate, S.T., 1989. Effect of a thromboxane receptor antagonist on PGD₂- and allergen-induced bronchoconstriction. *J. Appl. Physiol.* 66, 1685-1693.
- Canning, B.J., Chou, Y., 2008. Using guinea pigs in studies relevant to asthma and COPD. *Pulm. Pharmacol. Ther.* 21, 702-720.
- Capra, V., Habib, A., Accomazzo, M.R., Ravasi, S., Citro, S., Levy-Toledano, S., Nicosia, S., Rovati, G.E., 2003. Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation. *Eur. J. Pharmacol.* 474, 149-159.

427 Coleman, R.A., Smith, W.L., Narumiya, S., 1994. International Union of Pharmacology
 428 classification of prostanoid receptors: properties, distribution, and structure of the
 429 receptors and their subtypes. *Pharmacol. Rev.* 46, 205-229.
 430 Dahlen, S.E., Kumlin, M., 2004. Monitoring mast cell activation by prostaglandin D2 in vivo.
 431 *Thorax* 59, 453-455.
 432 Dawson, W., Boot, J.R., Cockerill, A.F., Mallen, D.N., Osborne, D.J., 1976. Release of novel
 433 prostaglandins and thromboxanes after immunological challenge of guinea pig lung.
 434 *Nature* 262, 699-702.
 435 Dube, G.P., Mais, D.E., Jakubowski, J.A., Brune, K.A., Utterback, B.G., True, T.A.,
 436 Rinkema, L.E., Kurtz, W.L., 1992. In vitro characterization of a novel TXA2/PGH2
 437 receptor ligand (S-145) in platelets and vascular and airway smooth muscle. *J.*
 438 *Pharmacol. Exp. Ther.* 262, 784-791.
 439 Evans, J.N., Adler, K.B., 1981. The lung strip: evaluation of a method to study contractility of
 440 pulmonary parenchyma. *Exp. Lung. Res.* 2, 187-195.
 441 Hamid-Bloomfield, S., Payne, A.N., Petrovic, A.A., Whittle, B.J., 1990. The role of
 442 prostanoid TP- and DP-receptors in the bronchoconstrictor effect of inhaled PGD2 in
 443 anaesthetized guinea-pigs: effect of the DP-antagonist BW A868C. *Br. J. Pharmacol.*
 444 100, 761-766.
 445 Held, H.D., Martin, C., Uhlig, S., 1999. Characterization of airway and vascular responses in
 446 murine lungs. *Br. J. Pharmacol.* 126, 1191-1199.
 447 Jonsson, E.W., Dahlen, S.E., 1994. Interactions between leukotrienes and histamine in the
 448 anaphylactic contraction of guinea pig lung parenchyma. *J. Pharmacol. Exp. Ther.* 271, 615-
 449 623.

450 Kiriyaama, M., Ushikubi, F., Kobayashi, T., Hirata, M., Sugimoto, Y., Narumiya, S., 1997.
 451 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid
 452 receptors expressed in Chinese hamster ovary cells. *Br. J. Pharmacol.* 122, 217-224.

453 Komoto, J., Yamada, T., Watanabe, K., Takusagawa, F., 2004. Crystal structure of human
 454 prostaglandin F synthase (AKR1C3). *Biochemistry* 43, 2188-2198.

455 Larsson, A.K., Back, M., Hjoberg, J., Dahlen, S.E., 2005. Inhibition of nitric-oxide synthase
 456 enhances antigen-induced contractions and increases release of cysteinyl-leukotrienes in
 457 guinea pig lung parenchyma: nitric oxide as a protective factor. *J. Pharmacol. Exp. Ther.*
 458 315, 458-465.

459 Larsson, A.K., Back, M., Lundberg, J.O., Dahlen, S.E., 2009. Specific mediator inhibition by
 460 the NO donors SNP and NCX 2057 in the peripheral lung: implications for allergen-
 461 induced bronchoconstriction. *Respir. Res.* 10, 46.

462 Larsson, A.K., Fumagalli, F., DiGennaro, A., Andersson, M., Lundberg, J., Edenius, C.,
 463 Govoni, M., Monopoli, A., Sala, A., Dahlen, S.E., Folco, G.C., 2007. A new class of
 464 nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and
 465 airway smooth muscle preparations. *Br. J. Pharmacol.* 151, 35-44.

466 Liu, F., Gonzalo, J.A., Manning, S., O'Connell, L.E., Fedyk, E.R., Burke, K.E., Elder, A.M.,
 467 Pulido, J.C., Cao, W., Tayber, O., Qiu, Y., Ghosh, S., Ocain, T.D., Hodge, M.R., Suzuki-
 468 Yagawa, Y., 2005. Pharmacological characterization of guinea pig chemoattractant
 469 receptor-homologous molecule expressed on Th2 cells (CRTH2). *Prostaglandins Other*
 470 *Lipid Mediat.* 76, 133-147.

471 Liu, M.C., Hubbard, W.C., Proud, D., Stealey, B.A., Galli, S.J., Kagey-Sobotka, A., Bleecker,
 472 E.R., Lichtenstein, L.M., 1991. Immediate and late inflammatory responses to ragweed
 473 antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and
 474 permeability changes. *Am. Rev. Respir. Dis.* 144, 51-58.

475 Lydford, S.J., McKechnie, K.C., Leff, P., 1996. Interaction of BW A868C, a prostanoid DP-
 476 receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein.
 477 Prostaglandins 52, 125-139.

478 Macchia, L., Hamberg, M., Kumlin, M., Butterfield, J.H., Haeggstrom, J.Z., 1995.
 479 Arachidonic acid metabolism in the human mast cell line HMC-1: 5-lipoxygenase gene
 480 expression and biosynthesis of thromboxane. Biochim. Biophys. Acta 1257, 58-74.

481 Magnussen, H., Boerger, S., Templin, K., Baunack, A.R., 1992. Effects of a thromboxane-
 482 receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced
 483 bronchoconstriction. J. Allergy Clin. Immunol. 89, 1119-1126.

484 Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., Kabashima, K., Sugimoto,
 485 Y., Kobayashi, T., Ushikubi, F., Aze, Y., Eguchi, N., Urade, Y., Yoshida, N., Kimura, K.,
 486 Mizoguchi, A., Honda, Y., Nagai, H., Narumiya, S., 2000. Prostaglandin D2 as a
 487 mediator of allergic asthma. Science 287, 2013-2017.

488 McKenniff, M.G., Norman, P., Cuthbert, N.J., Gardiner, P.J., 1991. BAY u3405, a potent and
 489 selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro. Br. J.
 490 Pharmacol. 104, 585-590.

491 Mita, H., Ishii, T., Akiyama, K., 1999. Generation of thromboxane A2 from highly purified
 492 human sinus mast cells after immunological stimulation. Prostaglandins Leukot. Essent.
 493 Fatty Acids 60, 175-180.

494 Monneret, G., Gravel, S., Diamond, M., Rokach, J., Powell, W.S., 2001. Prostaglandin D2 is
 495 a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood
 496 98, 1942-1948.

497 Norel, X., 2007. Prostanoid receptors in the human vascular wall. ScientificWorldJournal 7,
 498 1359-1374.

499 Norel, X., Walch, L., Labat, C., Gascard, J.P., Dulmet, E., Brink, C., 1999. Prostanoid
 500 receptors involved in the relaxation of human bronchial preparations. *Br. J. Pharmacol.*
 501 126, 867-872.

502 Norman, P., Cuthbert, N.J., McKenniff, M.G., Gardiner, P.J., 1992. The thromboxane
 503 receptors of rat and guinea-pig lung. *Eur. J. Pharmacol.* 229, 171-178.

504 O'Sullivan, S., Dahlen, B., Dahlen, S.E., Kumlin, M., 1996. Increased urinary excretion of the
 505 prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge
 506 supports mast cell activation in aspirin-induced airway obstruction. *J. Allergy Clin.*
 507 *Immunol.* 98, 421-432.

508 Okano, M., Fujiwara, T., Sugata, Y., Gotoh, D., Masaoka, Y., Sogo, M., Tanimoto, W.,
 509 Yamamoto, M., Matsumoto, R., Eguchi, N., Kiniwa, M., Isik, A.U., Urade, Y., Nishizaki,
 510 K., 2006. Presence and characterization of prostaglandin D2-related molecules in nasal
 511 mucosa of patients with allergic rhinitis. *Am. J. Rhinol.* 20, 342-348.

512 Parameswaran, K., Radford, K., Fanat, A., Stephen, J., Bonnans, C., Levy, B.D., Janssen, L.J.,
 513 Cox, P.G., 2007. Modulation of human airway smooth muscle migration by lipid
 514 mediators and Th-2 cytokines. *Am. J. Respir. Cell Mol. Biol.* 37, 240-247.

515 Ressmeyer, A.R., Larsson, A.K., Vollmer, E., Dahlen, S.E., Uhlig, S., Martin, C., 2006.
 516 Characterisation of guinea pig precision-cut lung slices: comparison with human tissues.
 517 *Eur. Respir. J.* 28, 603-611.

518 Roquet, A., Dahlen, B., Kumlin, M., Ihre, E., Anstren, G., Binks, S., Dahlen, S.E., 1997.
 519 Combined antagonism of leukotrienes and histamine produces predominant inhibition of
 520 allergen-induced early and late phase airway obstruction in asthmatics. *Am. J. Respir.*
 521 *Crit. Care Med.* 155, 1856-1863.

522 Sandig, H., Andrew, D., Barnes, A.A., Sabroe, I., Pease, J., 2006. 9alpha,11beta-PGF2 and its
 523 stereoisomer PGF2alpha are novel agonists of the chemoattractant receptor, CRTH2.
 524 FEBS Lett. 580, 373-379.

525 Selg, E., Andersson, M., Lastbom, L., Ryrfeldt, A., Dahlen, S.E., 2009. Two different
 526 mechanisms for modulation of bronchoconstriction in guinea-pigs by cyclooxygenase
 527 metabolites. Prostaglandins Other Lipid Mediat. 88, 101-110.

528 Selg, E., Lastbom, L., Ryrfeldt, A., Kumlin, M., Dahlen, S.E., 2008. Effects of selective and
 529 non-selective COX inhibitors on antigen-induced release of prostanoid mediators and
 530 bronchoconstriction in the isolated perfused and ventilated guinea pig lung.
 531 Prostaglandins Leukot. Essent. Fatty Acids 78, 89-97.

532 Sugimoto, H., Shichijo, M., Okano, M., Bacon, K.B., 2005. CRTH2-specific binding
 533 characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2-
 534 and indomethacin-induced agonist responses. Eur. J. Pharmacol. 524, 30-37.

535 Urade, Y., Eguchi, N., 2002. Lipocalin-type and hematopoietic prostaglandin D synthases as a
 536 novel example of functional convergence. Prostaglandins Other Lipid Mediat. 68-69,
 537 375-382.

538 van den Berge, M., ten Hacken, N.H., Cohen, J., Douma, W.R., Postma, D.S., 2011. Small
 539 airway disease in asthma and COPD: clinical implications. Chest 139, 412-423.

540 Vane, J.R., 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-
 541 like drugs. Nat. New Biol. 231, 232-235.

542 Wong, W.S., Bloomquist, S.L., Bendele, A.M., Fleisch, J.H., 1992. Pharmacological and
 543 histological examinations of regional differences of guinea-pig lung: a role of pleural
 544 surface smooth muscle in lung strip contraction. Br. J. Pharmacol. 105, 620-626.

545
 546

Figure legends

Fig. 1. Contractions induced by cumulative concentrations of (A and B) PGD₂ and (C and D) TP receptor agonist U46619 in guinea pig lung parenchymal strips. The experiments were performed in absence or presence of (A and C) the TP receptor antagonists SQ-29548 or (B and D) BAY u3405 (n=5-6). Data are presented as mean $\pm$ S.E.M..

Fig. 2. Contractions induced by cumulative concentrations of (A) 9 α ,11 β - PGF₂ and (B) PGF_{2 α} in guinea pig lung parenchymal strips. The experiments were performed in absence or presence of 1 μ M of the TP receptor antagonist SQ-29548 (n=5). Data are presented as mean $\pm$ S.E.M..

Fig. 3. Studies of the DP₁ receptor in guinea pig lung parenchymal strips. (A) Effect of cumulative concentrations of the DP₁ receptor agonist BW245C after precontraction with LTD₄ 10 nM and (B) effect of the DP₁ receptor antagonist BWA868C on PGD₂ induced contractions (n=5). Data are presented as mean $\pm$ S.E.M..

Fig. 4. Contractile responses to (A) PGD₂ and (B) the TP receptor agonist U46619 in airway and, pulmonary artery and vein in guinea pig precision cut lung slices. Data presented as % change of initial luminal area (n=4). Data are presented as mean $\pm$ S.E.M..

Fig. 5. Effect of the TP receptor antagonist SQ-29548 on cumulative doses of ovalbumin (0.001-10 μ g/ml) in absence and presence of 1 μ M SQ-29548 (n=4) in guinea pig lung parenchymal strips. Data are presented as mean $\pm$ S.E.M..

Table 1: Effects of the TP receptor antagonists on PGD₂ and U46619 induced contractions

Treatment	N	E_{max}	pEC₅₀	Hill slope
PGD ₂ (Control)	6	65.2±4.8	5.4± 0.3	0.6 ± 0.0
PGD ₂ + SQ-29548 0.01µM	6	78.9±0.7	4.9±0.1	0.6±0.0
PGD ₂ + SQ-29548 0.1µM	6	72.5±5.2	4.7±0.1 ^a	0.9±0.1 ^a
PGD ₂ + SQ-29548 1µM	6	50.1±7.1	4.2±0.1 ^c	1.7±0.1 ^c
PGD ₂ (Control)	5	75.7±3.5	5.2±0.2	0.6±0.0
PGD ₂ + BAYu3405 0.1µM	5	64.7±8.2	4.3±0.1 ^b	1.4±0.2 ^b
PGD ₂ + BAYu3405 1µM	5	49.2±15.1	4.0±0.2 ^c	1.9±0.1 ^c
U46619 (Control)	6	99.1±0.9	6.8±0.2	0.6±0.1
U46619 + SQ-29548 0.01µM	5	99.1±1.0	6.6±0.2	0.7±0.1
U46619 + SQ-29548 0.1µM	5	100.0±0.0	6.0±0.2 ^a	0.8±0.1
U46619 + SQ-29548 1µM	5	100.0±0.0	5.3±0.2 ^c	1.6±0.3 ^c
U46619 (Control)	6	98.6±1.2	7.2±0.4	0.5±0.1
U46619 + BAYu3405 0.01µM	5	99.8±0.2	6.5±0.2	0.7±0.2
U46619 + BAYu3405 0.1µM	5	100.0±0.0	5.4±0.1 ^c	1.1±0.2
U46619 + BAYu3405 1µM	5	97.9±2.1	5.0±0.1 ^c	1.6±0.2 ^c

Calculations of E_{max}, pEC₅₀ and Hill slope presented as mean ± S.E.M.. Significant differences from the agonists (controls) are indicated as ^aP<0.05, ^bP<0.01 or ^cP<0.001.

Table 2. Effects of the DP₁ receptor antagonist on PGD₂ induced contractions

Treatment	N	E_{max}	pEC₅₀	Hill slope
PGD ₂ (Control)	5	83.8 ± 6.4	4.6 ± 0.3	0.4 ± 0.0
PGD ₂ + BWA868C 0.1µM	5	81.5 ± 5.9	4.9 ± 0.1	0.5 ± 0.1
PGD ₂ + BWA868C 1µM	5	76.9 ± 7.4	5.0 ± 0.3	0.5 ± 0.1

Calculations for E_{max}, pEC₅₀ and Hill slope are presented as mean ± S.E.M..

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5